AYUSH Sector in India: Budget Boost or Overpromised Aspirations?
₹4,408 crore. That’s the amount allocated to the AYUSH sector in the Union Budget 2026–27, reflecting the government's growing optimism about traditional medicine systems as both a domestic health solution and a global economic opportunity. With a 66% hike in the National AYUSH Mission budget, funds earmarked for three new All India Institutes of Ayurveda, and resources to enhance herbal exports through the India–EU Free Trade Agreement (FTA), this appears to be a pivotal moment for AYUSH. Yet, beneath this financial enthusiasm lie critical questions about infrastructure adequacy, scientific validation, and integration with modern healthcare systems — questions that demand closer scrutiny.
The Policy Instruments at Play
The AYUSH sector operates within a multi-institutional framework. At its core is the National AYUSH Mission (NAM), which has been instrumental in co-locating AYUSH facilities in primary health centres (PHCs), community health centres (CHCs), and district hospitals. The allocation for NAM has jumped from ₹782 crore in 2025–26 to a substantial ₹1,300 crore in the current budget, with an emphasis on modernising dispensaries, upgrading infrastructure, and integrating AYUSH clinics into mainstream hospitals to promote preventive healthcare.
Additionally, the budget envisions setting up three All India Institutes of Ayurveda, designed to be the flagship research and training centres for traditional medicine. The ambition here is clear: replicate the success of AIIMS for scientific medicine within the AYUSH domain. On the international front, India’s partnership with the WHO Global Traditional Medicine Centre in Jamnagar aims to establish global benchmarks for traditional practices. These initiatives are further bolstered by ₹220 crore dedicated to AYUSH drug testing labs and pharmacies and the launch of the multilingual AI assistant Bharat-VISTAAR, specifically tailored to empower medicinal plant farmers.
The recent India–EU FTA introduces institutional certainty for AYUSH exports, allowing mutual recognition of lab certifications and facilitating easier mobility for practitioners. This could potentially make Indian herbal medicine the new turmeric latte in European markets — ubiquitous, trendy, and lucrative.
The Case for AYUSH: Expanding Soft Power and Economic resilience
The arguments for AYUSH are robust. First, it represents a unique model of preventive and personalised healthcare, often more affordable than modern medicine. Nearly 70% of India’s population relies on traditional medicine systems in some capacity, making AYUSH vital to bridging gaps in public health coverage in rural areas.
Economically, the sector is burgeoning. Between 2020 and 2026, the AYUSH ministry’s budget allocation more than doubled — from ₹2,122 crore to ₹4,408 crore — signaling growing policy attention. India’s exports of herbal medicine reached $447 million in 2025, up 65% from 2021, underscoring the global appetite for plant-based therapies. Furthermore, wellness tourism linked to AYUSH systems contributes over ₹30,000 crore annually.
On the international stage, AYUSH enhances India’s soft power. The new India–EU FTA offers trade protections for India’s Traditional Knowledge Digital Library (TKDL), shielding it from biopiracy. At the same time, it provides Indian practitioners easy access to European markets, further broadening the country’s cultural diplomacy footprint. Beyond economics, policy experts argue that positioning India as a global leader in setting research standards for traditional medicine bolsters our credibility in global health governance.
The Case Against: Scientific Gaps and Institutional Weaknesses
The optimism surrounding AYUSH, however, finds itself tempered by considerable challenges. Critics frequently point to the sector’s lack of reliable clinical trials and evidence-backed validation, undermining its credibility on global platforms. Despite the government’s focus, many AYUSH hospitals remain structurally deficient and understaffed, particularly in tier-III cities and rural districts.
Quality control in herbal medicines continues to be highly inconsistent. While the increase in allocation for drug-testing laboratories is welcome, the capacities of these facilities remain uneven across states. Take the case of Maharashtra—the state’s AYUSH dispensaries serve over 7 million people annually, but only five government labs are equipped for comprehensive safety testing.
Another critique is the rising support for “mixopathy,” the practice of blending traditional and modern medicine, without clear procedural guidelines. In December 2025, protests erupted among the medical fraternity, with the Indian Medical Association (IMA) arguing that such practices dilute scientific rigor. Even globally, this tension is visible: the EU’s cautious regulatory framework for herbal therapies contrasts with its openness to mobility under the FTA.
What Other Democracies Did: Lessons from Germany
Germany offers insights into balancing tradition with science. As the largest European market for herbal medicines, it has successfully integrated these therapies into its modern healthcare system. Physicians prescribing herbal remedies must adhere to stringent research-backed protocols enforced by the Federal Institute for Drugs and Medical Devices. This institutional approach has not only built trust but also facilitated exports worth €1.2 billion annually. The lesson for India is clear: integration without evidence-based validation risks both medical safety and global credibility.
Where Things Stand
India’s AYUSH sector is undoubtedly on a promising trajectory, backed by increased budgets and global trade agreements. But this expansion risks being undermined by weaknesses in clinical validation, infrastructure gaps, and fragmented regulatory oversight. The ₹4,408 crore allocation may mark a milestone, but the sector needs more than funds; it requires a pivot toward evidence-based practice, robust institution-building, and deeper integration with modern healthcare systems.
Real gains for AYUSH depend on addressing these structural limitations—because without convincing scientific underpinnings, India’s ambitions of leading global health might remain an overreach.
Practice Questions for UPSC
Prelims Practice Questions
- Statement 1: The AYUSH budget has more than doubled from 2020 to 2026.
- Statement 2: AYUSH systems are solely based on herbal medicine.
- Statement 3: The India–EU FTA includes provisions for AYUSH exports.
Which of the above statements is/are correct?
- Statement 1: Upgrading infrastructure at AYUSH clinics.
- Statement 2: Establishing All India Institutes of Ayurveda.
- Statement 3: Implementing a uniform pricing policy across all AYUSH medicines.
Which of the above statements is/are correct?
Frequently Asked Questions
What financial trends are evident in the AYUSH sector's budget allocation?
The AYUSH sector's budget allocation has increased significantly, growing from ₹2,122 crore in 2020 to ₹4,408 crore in 2026-27. This indicates the government's recognition of the sector's potential in both domestic health provision and international economic opportunities.
How does the AYUSH sector's role in traditional medicine contribute to public health in India?
AYUSH plays a crucial role in public health, particularly in rural areas, as nearly 70% of India’s population depends on traditional medicine. This sector supports preventive healthcare and helps bridge gaps in public health coverage, especially where modern healthcare facilities are limited.
What are the critical infrastructure and scientific validation challenges facing the AYUSH sector?
Despite increased funding, the AYUSH sector faces challenges related to inadequate infrastructure and a lack of reliable clinical trials. Many AYUSH hospitals remain understaffed and ill-equipped, which undermines the sector’s credibility and efficacy in providing quality healthcare.
What is the significance of the India–EU Free Trade Agreement (FTA) for the AYUSH sector?
The India–EU FTA is significant for the AYUSH sector as it facilitates the mutual recognition of lab certifications and opens European markets to Indian herbal medicine. This enhances the sector's global footprint and provides a framework for protecting traditional knowledge from biopiracy.
What concerns have been raised regarding the practice of 'mixopathy' in the AYUSH sector?
Critics have raised concerns about 'mixopathy,' which involves combining traditional and modern medicine without established procedural guidelines. This practice has led to protests from the medical community, fearing that it could dilute scientific rigor and compromise patient safety.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.